Murine malignant cells synthesize a 19,000-dalton protein that is physicochemically and antigenically related to the immunosuppressive retroviral protein, P15E by unknown
MURINE  MALIGNANT  CELLS  SYNTHESIZE A  19,000-DALTON 
PROTEIN  THAT  IS PHYSICOCHEMICALLY  AND 
ANTIGENICALLY  RELATED  TO  THE  IMMUNOSUPPRESSIVE 
RETROVIRAL  PROTEIN,  P15E* 
BY GEORGE J.  CIANCIOLO*, MARK E.  LOSTROM, MILTON TAM, AND 
RALPH SNYDERMAN 
From the Laboratory of Immune Effector Function, Howard Hughes Medical Institute, Division of 
Rheumatic and Genetic Diseases, Departments of Medicine, Microbiology, and Immunology, Duke 
University Medical Center, Durham, North Carolina 27710; and Genetic Systems Corporation, 
Seattle, Washington 98121 
Mononuclear phagocytes can play an important role in restricting the growth 
of neoplastic cells (1-3), but this function depends upon their ability to localize 
rapidly at sites of neoplastic transformation. Depression of the intrinsic migratory 
capabilities of mononuclear phagocytes might very well serve to potentiate the 
growth or metastasis of tumor cells. Several years ago the observation was made 
that  patients  with  a  variety  of neoplastic  diseases  had  depressed  monocyte 
chemotactic responses  (4-6)  and  that  these  depressed  responses  were  often 
reversed by surgical removal of the tumor or by immunotherapy (7, 8).  These 
findings led to  development of murine models with  which it  was shown that 
implantation of a variety of transplantable tumor lines into normal mice resulted 
in dramatic inhibition of their ability to accumulate macrophages at inflammatory 
foci  (9,  10),  to  resist  bacterial  infection  (11),  and  to  develop  delayed-type 
hypersensitivity responses (12). A major portion of the inhibitory activity found 
associated with  these tumors was contained in  low  molecular weight extracts 
prepared by sonication and ultrafiltration of the tumor cells (9,  10).  It was later 
shown that such activity could not be attributed to contamination with lactate 
dehydrogenase virus (13,  14) and that not only the tumors but the plasma and 
urine of mice bearing spontaneous mammary adenocarcinomas (15) or sponta- 
neous  iymphomas  (16)  were  able  to  inhibit  macrophage accumulation  when 
injected into normal mice. 
In  an  effort to  determine the source of the  tumor-associated inhibitors  of 
macrophage accumulation we examined various RNA tumor viruses and found 
that  low  molecular weight  extracts  prepared  from certain  oncogenic murine 
leukemia viruses (Friend, Moloney, Rauscher) inhibited macrophage accumula- 
tion  when they were injected into  normal  mice (17).  The purified retrovirai 
envelope protein P15E had similar inhibitory activity as well as physicochemical 
characteristics in  common with  the inhibitor  derived from tumor cells.  This 
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suggested  that  P15E  could  be  responsible  for  the  inhibition  of  macrophage 
accumulation caused by the retroviruses and perhaps by tumors themselves. 
We have now used metabolic labeling and monoclonal antibodies to examine 
six  different  murine  tumor  cell  lines  to  determine  whether  they  synthesize 
retroviral P15E or related proteins.  In addition,  using a  newly developed com- 
petition  ELISA  assay  for  P15E,  we  have  examined  a  spontaneous  mammary 
adenocarcinoma and  a  primary  20-methylcholanthrene (MCA)l-induced  fibro- 
sarcoma as well as  the ascites fluid of tumor-bearing mice for the presence of 
P15E-related  antigens.  We  have  also  determined  whether  the  inhibitors  of 
macrophage accumulation contained in primary murine tumors are antigenically 
related to P15E. 
Materials and Methods 
Mice.  Male C3H/HeN mice (MMTV-) were obtained from Charles River Kingston, 
Stone Ridge,  NY.  Male C3H/FeJ mice were obtained from Jackson  Laboratories, Bar 
Harbor, ME. 
Reagents.  Double density-gradient purified, Rauscher leukemia virus (RLV; 1.7 mg/ 
ml; 9.3 ×  10 ~l viral particles/ml) and murine mammary tumor virus (MMTV;  1.2 mg/ 
ml; 2.0 ×  10 ~l viral particles/ml) were purchased from Electro-Nucleonics Laboratories, 
Inc., Bethesda, MD. Tris (hydroxymethyl)aminomethane,  deoxycholic  acid (DOC), Triton 
X-100,  20-methylcholanthrene (MCA),  polyoxyethylene sorbitan  monolaurate (Tween 
20), guanidine HCI, bovine serum albumin Fraction V (BSA) and bovine serum albumin 
radioimmunoassay grade (RIA BSA) were all purchased from Sigma Chemical Co., St. 
Louis, MO. Sodium dodecyl sulfate (SDS), 2-mercaptoethanol (2ME), ammonium persul- 
fate, acrylamide, N,N'-methylene-bis-acrylamide (BIS), dithiothreitol (DTT) and Bio-Lyte 
carrier ampholytes were purchased from Bio-Rad Laboratories, Richmond, CA. Glycerol, 
N,N,N',N'-Tetramethylethylenediamine (TEMED), glycine, Nonidet P40  (NP40), and 
Coomassie Brilliant  Blue R-250  were obtained from Bethesda Research  Laboratories, 
Inc., Gaithersburg, MD. Bromphenol Blue was obtained from Fisher Scientific, Fair Lawn, 
N  J, urea from MCB,  Norwood, OH, and gelatin from Nutritional Biochemicals Corp., 
Cleveland, OH. 
Cells.  Tumor cell lines used included the Hep 129 hepatocarcinoma and BP8 fibro- 
sarcoma that were originally induced by MCA. Three variants (F1, F10, and BL6) of the 
B16 melanoma were kindly provided by I. J.  Fidler of the Frederick Cancer Research 
Center, and the RL 1 iymphoma was provided by C. Whisnant of Duke University. Friend 
leukemia virus (FLV) producing Eveline cells (fibroblasts) were provided by A. Langlois 
of Duke University. Nonmalignant cell lines were the STO and 3T3/BALB fibroblast 
cell lines from the American Type Culture Collection, Rockville, MD, and the 3T3/L1 
fibroblast cell line provided by S. Gidwitz of Duke University. Single cell suspensions of 
normal splenocytes were derived from a male C3Heb/FeJ mouse. 
Antibodies.  Ascites fluids containing monoclonal antibodies to two different epitopes 
of the murine retrovirus structural protein P 15E were obtained from male CB6FjJ mice 
(Jackson Laboratories, Bar Harbor, ME) injected intraperitoneally (i.p.) with 107 cultured 
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hybridoma  cells  4  d  after  a  priming  injection  of 0.5  ml  of pristane  (2,  6,  10,  14- 
tetramethylpentadecanei Aldrich Chemical Co., Milwaukee, WI). The two antibodies are 
designated  19F8 and 4F5 and have IgG2b and IgG2, isotypes respectively (18-20).  The 
ascites fluids for both lines contain  "-,2.5-4.0 mg specific antibody per ml as the parent 
myeloma line, BALB/c MOPC21 NS 1  /  1, secretes only light chains. Equal volumes of the 
two anti-P15E ascites fluids were combined as this technique enhances antibody affinity 
(21).  Both monoclonal anti-P15E isotypes bind Staphlococcus aureus (S. aureus) protein A. 
A control monoclonal antibody ascites fluid used was 4F2, an IgG2a antibody that reacts 
with human and murine cell lines and with mitogen-stimulated lymphoid cells and was 
kindly supplied by B. Haynes of Duke University. 
Rabbit antiserum to P15E was prepared using monoclonal antibody affinity-purified 
antigen from disrupted RLV. Normal rabbit serum (NRS) was obtained by bleeding the 
rabbits before the initial immunization. Rabbit antiserum to GP70 was kindly supplied by 
K. Weinhold of Duke University and rabbit antiserum to goat IgG was obtained from 
Miles Laboratories, Elkhart,  IN. Pooled normal mouse serum (NMS), containing  ~3-4 
mg/ml of IgG, was obtained from male C3H/HeN mice. Goat antibody to RLV reverse 
transcriptase was obtained from the  Biological  Carcinogenesis Branch  of the  National 
Cancer  Institute.  Goat antibodies to  RLV GP69/71  and P30  were obtained from the 
Viral Oncology Branch of the National Cancer Institute. Normal goat serum (NGS) was 
obtained from Gibco Laboratories, Grand Island, NY. 
[35S]Methionine  Labeling of Cells.  Nonadherent cells were washed once in RPMI 1640 
medium (Gibco Laboratories Grand  Island,  NY) containing  1.0  #M  L-metbionine and 
dialyzed 10% fetal bovine serum (FBS;  Gibco) (labeling medium). ~2-5  ×  107 cells were 
then suspended in 4 mi of labeling medium containing 0.5 mCi of [35S]methionine (>1,000 
Ci/mmol; New England Nuclear, Boston, MA), incubated 2 h  at 37°C in a humidified 
5% COs atmosphere, washed once, resuspended in RPMI 1640 containing 10% FBS and 
0.1  mM L-methionine (complete medium), and incubated an additional  2 h  at 37°C  in 
humidified 5% CO2.  The cells were then washed twice with cold FBS-free RPMI  1640, 
the cell pellet resuspended in 2 ml of NDS detergent buffer (1% NP°40, 0.5% DOC, 0.1% 
SDS, 0.4 M NaCI, 0.02 M PO4, pH 8.0), and the detergent extract sonicated. The extract 
was  centrifuged  for  20  min  at  27,000  g  and  4°C,  the  supernatant  removed and  the 
radioactivity determined. Labeling in this manner usually resulted in ~-3-4 ×  10 s cpm of 
labeled extract,  ~95% of which were trichloroacetic acid precipitable.  1 ml of formalin- 
fixed S.  aureus  (Pansorbin,  7%  wt/vol;  Calbiochem-Behring Corp.,  La Jolla,  CA)  was 
added for 30 rain at 37°C, the Pansorbin pelleted by centrifugation at 40,000 g and 4°C 
for 30 min, the supernatant removed, and the radioactivity determined. This preclearing 
step routinely removed <5% of the radiolabeled proteins. 
Adherent  cells (B16,  STO,  and  3T3  lines) were grown  to near confluence,  washed 
twice with labeling medium and then overlaid with 4 ml of labeling medium containing 
0.5 mCi of [35S]methionine. The flasks were incubated for 2 h at 37 °C in humidified 5% 
CO~,  the  labeling  medium  removed,  the  adherent  cells  washed  twice  with  complete 
medium, and incubated an additional 2 h at 37°C with  12 mi of complete medium. The 
adhered cells were washed three times with cold FBS-free RPM I 1640, and then solubilized 
with 2 ml of NDS detergent buffer. 
Mitogen-stimulated  Spleen  Cells.  1 ml volumes of normal splenocytes at 2 ×  106 cells/ml 
in complete medium were incubated for 48 h at 37°C in humidified 5% CO2 with either 
Phytohemagglutinin (PHA; 0.5  ~g/ml; Wellcome Reagents Limited, Beckenham, Eng- 
land) or concanavalin A (Con A; 1.0 ~g/ml; Miles Laboratories, Inc.). The PHA- or Con 
A-stimulated cells were separately pooled,  washed in  labeling medium and  2-3  ×  107 
viable cells labeled. Cell viability was >70% by trypan blue dye exclusion. 
Radioimmunoprecipitation  of Cell Extracts.  Cell extracts (~ 150-300 #1) containing 25 × 
106 cpm were incubated overnight at 4°C with  10 #1 of either anti-P15E, 4F2 antibody, 
or NMS. 50 #1 of Pansorbin was added to each extract for an additional 3 h at 4°C, the 
Pansorbin pelleted by centrifugation and the pellet washed four times with  NDS.  The 
pellet was then resuspended in 150 #1 of SDS sample buffer (0.125 M Tris-HC1, pH 6.8; 
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room temperature, the Pansorbin pelleted by centrifugation at 12,000 g and 4°C for 15 
min, the supernatant remo,bed, and the radioactivity determined. Immunoprecipitations 
with goat antibodies to viral proteins were performed in a similar manner except that 10 
ul of rabbit antiserum to goat IgG was added for an additional overnight incubation and 
100 tfl of Pansorbin was used to bind immune complexes. 
SDS-Polyacrylamide Gel  Electrophoresis (PAGE).  SDS-PAGE  gels  were  run  using  the 
method of Laemmli (22) and nonlinear 5-15% gradients. Stained gels were enhanced for 
autoradiography (ENSHANCE;  New England  Nuclear) and dried  under vacuum using 
gentle heat. X-Omat AR film (Eastman Kodak, Rochester, NY) was used for fluorography 
of the dried gels. 
Two-dimensional Gel Electrophoresis.  [3~S]Methionine-labeled  extracts of the  F10  and 
BL6 variants of the B16 melanoma and ~SI-labeled disrupted RLV were immunoprecip- 
itated  with  monoclonal anti-P15E  or  NMS  and  Protein-A  Sepharose  (Pharmacia  Fine 
Chemicals, Piscataway, NJ). The bound proteins were eluted with 2% SDS and 5% 2ME, 
adjusted to 4% Triton X-100 and 0.8 M urea, and isoelectric focused for 14 h at 300 V 
in  12-cm tube gels composed of 4.5% acrylamide, 4% Triton X-100, 8  M urea, and 2% 
ampholytes (pH 3-10).  The focused gels were then electrophoresed on a  nonlinear 5- 
15% gradient SDS slab gel as described above, the slab gels enhanced for fluorography 
and put up for autoradiography. 
SDS-PAGE and Western Blotting of Viral Proteins.  Purified RLV was detergent-disrupted 
and  50 #g of viral protein electrophoresed in  each sample lane of a  5-15%  nonlinear 
gradient gel. The proteins were then  electrophoretically transferred to activated APT 
paper (2-aminophenylthioether; Bio-Rad Laboratories) at 4°C for 14 h using 3 V/cm of 
distance across  the  electrodes.  The  blotted  proteins  were  incubated  for  1 h  at  room 
temperature with 50 ml of either mouse monoclonal or rabbit anti-P15E (1:1,000 in Tris 
gelatin buffer [0.15  M  NaC1, 0.005  M EDTA, 0.05  M Tris-HCl, 0.25%  gelatin, 0.05% 
NP-40, 0.1% BSA, pH 7.4]) or with 50 ml of either NMS or NRS (1:1,000 in Tris-gelatin 
buffer), washed four times for 15 rain with 50 ml of Tris-gelatin buffer, and incubated 
for 1 h at room temperature in freshly iodinated S. aureus protein A (specific activity ~5 
/zCi/~g) at a concentration of 106 cpm/ml in Tris-gelatin buffer. They were then washed, 
dried, and put up for autoradiography using an intensifying screen. 
Detergent-solubilized Cell Extracts.  Hep  129,  BP8,  and  the  three variants of the  B16 
melanoma were solubilized at  l0 s celis/ml  using NDS  detergent  buffer.  A  single  cell 
suspension prepared from a spontaneous mammary adenocarcinoma from a female C3H/ 
HeN mouse was adjusted to 108 cells/ml and solubilized. Liver tissue from a sex- and age- 
matched mouse was homogenized using a tissumizer (Tekmar Co., Cinncinnati, OH) and 
adjusted to the same packed volume as the mammary adenocarcinoma cells before their 
solubilization. Fibrosarcomas were induced in the right thighs of 6-8-wk old male C3H/ 
HeN mice by the subcutaneous injection of 5 mg of MCA in 0.5 ml of olive oil. Control 
mice were injected with the olive oil alone. Tumors developed 8-12 wk after injection, 
When  the tumors were  1.0-1.5  cm in diameter they and control tissues (liver, kidney, 
spleen) were removed from three tumor-bearing animals. Muscle tissue from the olive oil 
injected leg and liver, kidney, and spleen were removed from three control mice. The 
different tissues from either the tumor bearing or control mice were standardized to 200 
mg wet weight per ml of NDS detergent buffer, homogenized, sonicated, centrifuged for 
20 rain at 27,000 g and 4°C, and the supernatants removed. All tissue and cell extracts 
were negative for protease activity using a casein hydrolysis method (Bio-Rad Laborato- 
ries). 
Competition ELISA Assay for P15E.  Material  to be  tested  for P15E  (see  below) was 
diluted in NDS detergent buffer. Ascites fluids were first diluted  1:1  with 2 x  NDS and 
then further diluted in  1 x  NDS.  Diluted samples were mixed 1:1  (vol/voi) with rabbit 
anti-P15E (1:20,000  in 0.05  M  PO4-saline, pH 7.5, containing  1%  RIA BSA and 0.5% 
Tween 20) or buffer and incubated overnight at 4°C. The control was rabbit anti-P15E 
(1:20,000) diluted  1:1  with NDS. 50 ~1 of samples to be tested were then added to each 
of duplicate  wells  of a  RLV-coated polystyrene plate.  The plate was incubated  1 h  at 
37°C, washed 5x with wash buffer (0.05 M PO4-saline, pH 7.5, containing 0.5% Tween CIANCIOLO  ET  AL.  889 
20), and 50 #1 per well of peroxidase-conjugated goat anti-rabbit IgG (1:3,000 in wash 
buffer containing 1% RIA BSA) (Tago, Inc., Burlingame, CA) was added for 1 h at 37°C. 
The plate was washed 5x and 50 ~1 per well of peroxidase-conjugated swine anti-goat 
IgG (1:3000; Tago) was added for 1 h at 37°C. The plate was washed 5x and 200 t~l per 
well ofTMB substrate (3,3',5,5'-tetramethylbenzidine; Litton Bionetics, Kensington, MD) 
in 0.1  M citric acid, pH 4.0, containing 0.3% H202 was added. The plate was allowed to 
sit at room temperature to allow color development, and read on a Titertek Multiskan 
automated plate reader (Flow  Laboratories, McLean, VA)  with a  405-nm filter. Each 
plate was read several times during the course of color development. Color development 
was linear to ~ 0.5 absorbance units so assays were terminated when the absorbance (ABS) 
of the positive controls (antibody plus NDS) was "-,0.3. Percent inhibition of rabbit anti- 
pl 5E binding was calculated as 
% Inhibition --- ABS40~ Control -ABS40s Sample x  100. 
ABS405 Control 
The  absorbance  values  for  samples  incubated  with  antibody were  determined  after 
subtracting any absorbance generated by samples incubated with buffer only. These latter 
values never exceeded 10% of the absorbance values of antibody plus sample and generally 
were <5%.  A  standard curve  was  established for inhibition of anti-P15E binding by 
detergent disrupted RLV using data from four separate experiments. Values for inhibition 
of binding by cell extracts were compared to the RLV standard curve and expressed as 
the number of viral particles giving similar inhibition. The values for all experimental 
samples were calculated from the dilution of sample giving 50% inhibition of rabbit anti- 
P 15E binding. In 50 sets of duplicates examined, the average standard deviation for the 
mean was <8.4%. 
Macrophage Accumulation Inhibition Assay.  Macrophage accumulation 2 d after an i.p. 
injection of 35 vg of PHA was determined for tumor extract treated or control mice as 
previously described (15). Statistical  significance was determined using Student's t-test. 
Results 
Spec~city  of Murine Monoclonal and Rabbit Polyclonal Anti-Pl5E.  To verify the 
specificity of the monoclonal anti-P 15E, the antibody mixture was reacted with 
electroblotted proteins of P15E-containing  RLV, followed by incubation with 
125I-3. aureus protein A and autoradiography. Two distinct bands, corresponding 
to calculated molecular weights of 19,000 and 17,000 daltons, were detected by 
the anti-P 15E (Fig. 1). These bands represent P 15E and its degradation product, 
P12E (23).  No reactivity was detected on the blot exposed to NMS.  The same 
pattern of reactivity was seen using either monoclonal antibody alone (not shown) 
so  all further  experiments  were  performed  using the  combined  (~'~a and  ~'2b) 
antibodies. 
The  rabbit  antibody  to  P15E  also  reacted  primarily  with  the  19,000-  and 
17,000-dalton protein bands detected by the murine monoclonal anti-P 15E (Fig. 
1). The reactivity of a rabbit antibody to retroviral GP70 is shown in Fig. 1, lane 
E,  in  order  to  verify  that  the  higher  molecular  weight  viral  proteins  were 
successfully transferred by the blotting techniques used.  No  reactivity was de- 
tected on the blot exposed to NRS. The enhanced sensitivity obtained by use of 
a  polyclonal antiserum is illustrated by the fact that the autoradiograph of the 
rabbit  anti-P15E  required  only  30  rain  of film  exposure  while  that  of  the 
monoclonal anti-P 15E required  16 h of exposure for comparable intensity. 
Radioimmunoprecipitation  of Cancerous  or  Normal  Cells with  Monoclonal  Anti- 
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FIGURE  1.  Specificity of murine  monoclonal  and  rabbit  polyclonal antibodies  to  P15E. 
Detergent-disrupted  RLV proteins were separated using SDS-PAGE,  electrophoretically trans- 
ferred to APT paper, the paper cut  into  strips, and the  strips incubated  with (A) murine 
monoclonal anti-P15E, (B) normal mouse serum, (C) rabbit polyclonal anti-Pl5E,  (D) normal 
rabbit serum, and (E) rabbit anti-GP70. The strips were incubated with 125I-Protein A and 
then exposed for autoradiography.  K, kdaltons. 
FIGURE 2.  Radioimmunoprecipitation  of [sSS]methionine-labeled cultured  murine  tumor 
cells. The following cell lines were labeled, extracted,  and immunoprecipitated  with mono- 
clonal anti-P15E  (A-G)  or  monoclonal  4F2  (a-g):  Hep  129, B16BLG, B16F1, B16FI0, RL1, 
Eveline, and BP8. 
detergent extracted and immunoprecipitated with anti-P15E and formalin-fixed 
S.  aureus.  The  immunoprecipitated  proteins  were  analyzed  by SDS-PAGE  fol- 
lowed  by  gel  fluorography.  Control  antibodies  used  were  monocional  4F2  or 
NMS.  As  shown  in  Fig.  2,  lane  F,  Eveline  cells,  which  are  FLV-producing 
fibroblasts, synthesize a  19,000-dalton  protein corresponding to P15E.  Because 
these cells are actively producing viral particles this result  was expected.  Fig.  2 
also shows that the Hep  129,  BP8,  RL1, and three B16  melanoma variants also 
produced the  19,000-dalton  band corresponding to P15E.  The same number of CIANCIOLO  ET  AL.  891 
radioactive counts (80K) was applied to each of the lanes in Fig. 2. The amounts 
of radioactivity precipitated by anti-P 15E and monoclonal 4F2 for the Eveline 
and tumor cell lines were essentially the same for each cell type. The radioactivity 
precipitated by NMS was approximately one-third to one-sixth of that precipi- 
tated by anti-P15E or 4F2. In other experiments not shown, gels containing the 
same  amounts  of radiolabeled  counts  from  anti-P15E  and  NMS  precipitates 
demonstrated that the  19,000-dalton band was specific for anti-P15E.  Because 
the lower amounts of radioactivity associated with NMS precipitates necessitated 
much longer fluorography times these samples were not routinely run on the 
gels. The precipitates obtained with 4F2 are shown to illustrate the proteins that 
are precipitated  in  reactions involving a  monoclonal antibody that  recognizes 
determinants other than P15E. All of the cell lines shown in Fig. 2 except RL1 
were examined by electron microscopy for the presence of type C viral particles. 
Viral particles were readily detectable in the FLV infected Eveline cells whereas 
none  were  found  in  the  other  five cell  lines  examined (data  not  shown).  In 
addition,  autoradiograms  of gels  of the  three  B16  cell  lines  that  had  been 
immunoprecipitated with goat antibodies to RLV reverse transcriptase, GP69/ 
71 or P30 did not indicate the presence of any of these proteins in the malignant 
cells (data not shown). 
Fig. 3 illustrates autoradiograms of immunoprecipitated extracts from normal 
or mitogen-stimulated splenocytes or from three different nontransformed mu- 
rine fibroblast  cell lines.  None of the nonmalignant cells contained sufficient 
amounts of radiolabeled  P15E  to  be  detected by  immunoprecipitation using 
monoclonal anti-P15E. The same number of radioactive counts (70K) was applied 
to each lane for all three splenocyte samples but the number of counts precipi- 
tated from the fibroblast extracts made it necessary to standardize these samples 
to 30K per lane and use a correspondingly longer autoradiography developing 
time. For reference purposes, lane A of Fig. 3 contains the radiolabeled immu- 
noprecipitate from a B 16m.6 extract incubated with monoclonal anti-P 15E. 
Inhibition  of Immunoprecipitation  of  Tumor  Cell-Associated  PI5E  by  RLV  Ex- 
tract.  To  verify that  the  19,000-dalton  protein precipitated  from tumor cell 
FIGURE 3.  Radioimmunoprecipitation of [sSS]methionine-labeled cultured murine spleno- 
cytes and fibroblasts. The following cells were labeled, extracted,  and immunoprecipitated 
with monoclonal anti-P15E (A-G) or monoclonal 4F2 (a-g): B16BL6, unstimulated cultured 
splenocytes, PHA stimulated splenocytes, Con A-stimulated splenocytes, STO, 3T3/BALB, 
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extracts was antigenicaily related to P 15E, we immunoprecipitated a [35S]methi- 
onine-labeled extract of B16BL6 melanoma cells with anti-P15E  that  had been 
preincubated  for  30  min  at  37°C  with  either  buffer,  800  #g  of detergent- 
disrupted RLV, or 800 #g of detergent-disrupted MMTV. Preincubation of anti- 
P15E with buffer or MMTV, a  virus that does not contain P15E (24), had no 
effect on its ability to precipitate the 19,000-dalton protein from the B 16 extract 
(Fig.  4).  However, preincubation of the anti-P15E with P15E containing RLV 
prevented the precipitation of most of the 19,000-dalton protein synthesized by 
the tumor cells. 
Two-dimensional  Gel  Electrophoresis  of  Tumor  and  Viral  Anti-P15E  Precipi- 
tates.  Anti-P 15E immune precipitates from B 16F10 and B16BL6 [35S]methionine- 
labeled extracts and  ~25I-labeled  disrupted  RLV were separated by isoelectric 
focusing in  a  pH  3-10  gradient and  then  subjected to electrophoresis into a 
nonlinear 5-15%  gradient SDS slab gel.  As shown in  Fig.  5,  both the tumor- 
derived and viral precipitates contained proteins of "~ 19,000 daltons that focused 
between pH 7.4 and pH 8.4.  Precise comparison of isoelectric points cannot be 
made  however,  since  the  RLV  and  tumor  extracts,  by  necessity,  were  not 
radiolabeled with the same isotope.  Nonetheless, the strong similarity between 
the tumor and virus profiles suggest that the  19,000-dalton proteins present in 
both are not only antigenically related but physicochemically similar as well. 
Quantification  of P15E Associated with  Cancerous Cells or Ascites.  Cell extracts 
were prepared from Eveline, Hep 129, BP8, three variants of the B 16 melanoma, 
and a spontaneous mammary adenocarcinoma and were tested for the presence 
of P15E antigen using a  competition ELISA assay. For comparative purposes, 
the inhibition  of anti-P15E binding by cell extracts or ascites is given as viral 
particle equivalents (VPE); i.e., the number of detergent-disrupted RLV particles 
giving similar inhibition.  As previously stated however, except for the Eveline 
cells, the tumor lines used were free of any detectable viral particles. The results 
shown in Table I indicate that the cultured murine tumor cells contained material 
FIGURE 4.  Inhibition of precipitation of [35S]methionine-labeled P1 5E from BI 6BL6 cells by 
disrupted  RLV.  Extract prepared  from  [sSS]methionine-labeled B16BL6 cells was  incubated 
with monoclonal anti-P15E that had been preincubated with either (A) buffer, (B) disrupted 
RLV, or (C) disrupted  MMTV.  Lane D is the precipitate obtained from the B16BL8 extract 
incubated with monoclonal 4F2 and is shown to illustrate the non-P1 5E related binding. CIANCIOLO  ET  AL.  893 
FIGURE 5.  Two-dimensional gel electrophoresis of anti-Pl 5E immunoprecipitates of [~sS]- 
methionine-labeled B16~10 (A), B16nL6 (B), or of 125I-labeled detergent disrupted RLV (C). The 
isoelectric focusing and electrophoresis in the second dimension were carried out as described 
in the text. 
TABLE  I 
Quantification of P15E Associated With Murine Neoplasms 
Source of material*  Viral particle 
equivalents  at 
Eveline cells  2.4 ×  101° 
Hep 129 cells  4.4 ×  109 
B16vl ceils  3.3 ×  109 
B16rlo cells  2.5 ×  109 
BP8 cells  2.0 ×  109 
Spontaneous mammary tumor cells  1.8 ×  109 
Hep 129 ascites  6.8 ×  l0  s 
B16BL6 ceils  5.9 ×  l0  s 
Liver  None detected  j 
Control ascites  None detected 
Normal mouse serum  None detected 
Protein A purified immunoglobulins  !  None detected 
* Cells standardized to 10  s cells/ml and solubilized in N DS detergent. 
at Number of detergent-disrupted RLV particles giving equivalent inhibi- 
tion of rabbit anti-Pl 5E binding per milliliter of extract. 
0 Lower limit of detection ~3  ×  l0  T. 
! Purified from 4F2 ascites fluid. 
reactive with anti-P15E. The virus-producing cell line, Eveline, contained at least 
five times as much P15E antigen as the other cell lines tested. The spontaneous 
mammary adenocarcinoma cells contained at least  20  times as much P15E as 
liver tissue that had <3.0 X 107 VPE, the lower limit of detection for our assay. 
Ceil-free ascites fluid from C3H/HeN mice injected 7  d  earlier with  1 ×  106 
Hep 129 cells contained an amount of P 15E antigen per milliliter of ascites fluid 
that would be equal to that found in ,~ 15 X 106 Hep 129 cells. Since each mouse 
contained  "--5-6  ml of ascites fluid the amount of PI5E  recovered would be 
equivalent to ~75-90 x  10  ~ Hep  129 cells.  We estimate from previous studies 
that the number of Hep  129 cells in the peritoneal cavity at this time would be 
"~ 150 ×  106. Noncancerous ascites fluid, which was obtained from the peritoneal 
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TABLE  II 
Quantification of P15E Associated With Methylcholanthrene-induced 
Fibrosarcomas 
Tissue*  Viral particle equivalents* 
I.  Tumor-bearing  mice 
Fibrosarcoma  1.4 ×  101° 
Liver  None detected  ~ 
Kidney  None detected 
Spleen  None detected 
II.  Control  (olive oil-injected) mice 
Muscle  None detected 
Liver  None detected 
Kidney  None detected 
Spleen  None detected 
* Tissue standardized to 200 mg wet weight/ml and solubilized. 
* Number of detergent disrupted RLV particles giving equivalent inhibi- 
tion of rabbit anti-P  15E binding  per ml of extract. 
J Lower limit of detection ~ 3 ×  107. 
TABLE  III 
Effect of Monoclonal Anti-P15E on Inhibitory  Activity of Tumor Extracts* 
Accumulated 
Expt  Mice injected with:  M~b (× 106 +  Percent 
inhibition  P  SEM) 
]  Buffer  6.6 -+ 0.8 
Tumor extract  1.2 + 0.2  82  <0.001' 
Spleen extract  7.1 + 0.9  0  >0.6* 
Tumor extract absorbed  4.5 + 0.4  32  <0.0010 
with anti-P  15E 
2  Buffer  1.9 + 0.1 
Tumor extract  0.3 + 0.1  84  <0.001' 
Tumor extract absorbed  1.8 + 0.3  5  <0.001 ~ 
with anti-P  15E 
Tumor extract absorbed  0.5 + 0.1  74  >0.30 
with IgG2, 
* Extracts  were  incubated with buffer or buffer containing antibody for  1 h 
(expt.  1) or 3 h (expt. 2) at 4°C, absorbed with Protein A Sepharose, and the 
extracts  then injected  into the thighs of five normal C3H/HeN mice which 
were 30 (expt.  1) or 5 (expt. 2) wk old. Peritoneal macrophage  accumulation 
in response to 35 ug of PHA was calculated as previously described (15). 
* Compared with buffer control. 
0 Compared with tumor extract. 
adjuvant and which contained "-33%  more protein than the  Hep  129  ascites, 
had  no detectable levels of P15E.  Normal mouse serum, adjusted to  the  same 
protein concentration as the  Hep  129 ascites, and protein A-purified immuno- 
globulins from a  4F2 ascites were also both negative for P15E. 
MCA-induced primary fibrosarcomas and various control tissues were exam- 
ined for the presence of PI 5E using the competition ELISA assay. The carcino- 
gen-induced tumor tissue contained the equivalent of 1.4  x  10 ]° RLV particles 
per  milliliter of tissue  while  the  control  tissues  from  both  tumor-bearing and CIANCIOLO  ET  AL.  895 
control mice were below the limit of detection (Table II). 
Effect  of Monoclonal  Anti-P15E  on Macrophage  Inhibitory  Activity  of MCA-induced 
Fibrosarcomas.  Extract prepared from 40 ug wet weight of MCA induced fibro- 
sarcoma was incubated for 1 or 3 h at 4°C with either buffer, monoclonal anti- 
P15E (8 ng), or myeloma immunoglobulins of the same isotype and concentra- 
tion.  Immunoglobulin was removed by Protein A  Sepharose and the extracts 
injected into the thighs of normal mice, followed 24 h  later by an i.p. injection 
of PHA.  As  shown  in  Table  III,  tumor  extract incubated with  buffer alone 
inhibited  macrophage accumulation by  82-84%.  Extract  prepared  from  the 
spleens of the tumor bearing animals did not inhibit macrophage accumulation. 
Incubation of the tumor extract with monclonal anti-P 15E removed 61% of the 
inhibitory activity in experiment 1 and 94% of the inhibitory activity in experi- 
ment 2.  The lower number of accumulated macrophages in experiment 2  can 
be attributed to the younger age (5 w) of mice used in this experiment. Incubation 
of the tumor extract with myeloma IgG~a had no significant effect on the tumor 
associated inhibitory activity. 
Discussion 
We  have  previously shown  that  murine tumor cells and  certain  oncogenic 
murine viruses contain low molecular weight factors capable of inhibiting mac- 
rophage accumulation at inflammatory foci (9,  10,  13,  15,  17).  The inhibitory 
activity of the oncogenic viruses was found to reside in the retroviral envelope 
protein P15E (14). Of interest were the similar physicochemical characteristics, 
of P 15E and the antiinflammatory agent from tumor cells, in regards to molecular 
size  and  charge  (25).  We  therefore determined whether murine tumor  cells 
contained P 15E. Using metabolic labeling followed by immunoprecipitation with 
monoclonal antibodies, we have now shown that all six different murine tumor 
cell lines examined synthesize a protein that is antigenically related to retroviral 
P15E.  Immunoprecipitation of the P I 5E-related protein was blocked by prein- 
cubation of monoclonal anti-P15E with detergent-disrupted RLV, a virus known 
to contain P 15E (19). In contrast, preincubation of the anti-P 15E with non-P 15E 
containing MMTV had no effect. The immunoprecipitated P 15E-related protein 
was found only in malignant cells; unstimulated and mitogen-stimulated spleno- 
cytes as well as  three different murine fibroblast  cell  lines  were all  negative. 
Furthermore, in  the two malignant cell lines examined, the tumor associated 
19,000-dalton proteins showed a pattern in isoelectric focusing similar to that of 
RLV P15E, suggesting that the tumor and viral proteins were not only antigen- 
ically but physicochemically similar. Thus many commonly used tumor cell lines 
synthesize  a  protein  that  is  at  least  very  similar,  if  not  identical  with,  the 
immunosuppressive protein P15E.  Type C viral particles were not detected by 
electron microscopy in our cultured tumor lines although they were readily seen 
in vitally infected Eveline cells. We cannot rule out the possibility, however that 
the tumor cell lines contain a lower number of C-type viruses than are detectable 
by electron microscopy. However, immunoprecipitation of [35S]methionine-la- 
beled extracts of the three B16  melanoma lines with goat antibodies to  RLV 
reverse transcriptase, GP69/71, or P30 did not result in specific precipitation of 
these proteins from the tumor extracts. Under identical conditions these same 896  TUMOR  CELLS  CONTAIN  RETROVIRAL  P15E-RELATED  ANTIGEN 
antibodies precipitated the appropriate proteins from 125I-labeled RLV. Thus we 
consider it  highly  unlikely  that  the  synthesis of the  P15E  related protein  is 
associated  with  viral  particle  formation.  In  any  case,  investigators  must  be 
cognizant  of the  probability  that  murine  tumor  lines  routinely  synthesize  a 
protein antigenically related to an immunosuppressive viral protein even in the 
absence of detectable virus particles. 
The possibility that oncogenic transformation in vivo leads to the expression 
of a retroviral related protein is confirmed by the data showing expression of a 
P15E-related antigen in both a  spontaneous mammary adenocarcinoma and a 
carcinogen induced-primary fibrosarcoma.  The  use of metabolic labeling and 
immunoprecipitation to identify this antigen in these tissues was precluded by 
the poor viability of cells obtained from dissected tumors and their relatively low 
incorporation of the methionine label. The development of a sensitive competi- 
tion ELISA assay for P15E utilizing a polyclonal rabbit antiserum did, however 
allow the quantification of anti-P15E reactive material not only in the tumors, 
but in a variety of other tissues. Although the limits of the assay prevented the 
conclusion that  noncancerous tissues  contained no  P15E  related antigen,  the 
data indicates that neoplastic tissues contain substantially higher levels of this 
protein. 
Previously, investigators have reported finding type C virus particles in some 
cell lines (26, 27) as well as in transplanted tumors (28, 29). Other investigators 
have shown that retroviruses or retroviral proteins can be induced in a  variety 
of cultured mouse cell lines by chemical mutagens such as 5-azacytidine (30) or 
by mitogens combined with 5-bromo-2'-deoxyuridine (31) and that messenger 
RNAs  corresponding to  retroviral  genes can be elicited from carcinogen- or 
radiation-transformed fibroblasts  (32).  Fischinger et al.  (33)  have recently re- 
ported the expression of a unique surface murine leukemia virus recombinant- 
like glycoprotein on a  virus-free, X  ray-induced lymphoma. The mechanisms 
leading to the synthesis of the 19,000-dalton, P 15E-related protein by the tumor 
cells examined in the present study were not determined, but intact viruses were 
seen only in the FLV-infected Eveline cells. The inability to detect other viral 
proteins suggests that this protein, although antigenically and physicochemically 
similar to RLV P15E,  may be cellular in origin. Although we did not examine 
the culture supernatants of the various cell lines to determine whether they were 
secreting as well as synthesizing P15E related proteins,  the data showing such 
materials in the ascites fluid of mice injected intraperitoneally with Hep 129 cells 
suggests that this occurs in vivo. 
The demonstration in common laboratory tumor cell lines of an immunosup- 
pressive, virally related protein is certainly of interest, but of greater importance 
is the finding of high levels of these proteins in primary tumors arising in vivo. 
We have previously postulated that tumors might subvert immune surveillance 
through the release of soluble antiinflammatory factors and  that  such factors 
might play their most important role during the early stages of tumor growth 
(9,  10,  13). Our previous studies indicated that as little as 2 ng of disrupted RLV 
could inhibit macrophage function in normal mice (17). The present studies have 
found the equivalent of more P15E antigen than that derived from  100 ng of 
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Furthermore, 40 ~g wet weight of such tissue inhibited macrophage accumulation 
in normal mice by >80%. The inhibitory activity was almost completely removed 
by absorption  with  monoclonal antibody  to  P15E,  suggesting that  the  P15E 
related tumor proteins are also immunosuppressive as we have previously shown 
for retroviral P 15E (17).  Thus, it is conceivable that even at the earliest stages 
of neoplastic growth enough viral P15E or its cellular counterpart is released to 
affect immune function either systemically or locally. While our previous studies 
have shown that P15E inhibits macrophage function, others have demonstrated 
that  it  also  inhibits  lymphoproliferative responses  in  cats  and  man  (34)  and 
disrupted  RLV  has  been  shown  to  suppress  the  Con  A  response  of murine 
lymphocytes (35).  Thus the production of this or a  closely related protein by 
malignant cells might allow them to curtail many immunological defenses against 
tumor cells. 
Recently, we made the observation that human cancerous effusions contained 
low molecular weight factors that inhibited the responses of normal monocytes 
to  chemotactic stimuli  (36).  Interestingly, any of three different monoclonal 
antibodies to P 15E absorbed the inhibitory activity from these cancerous fluids 
(36).  This suggested that human cancerous effusions contained a  protein anti- 
genicaily related to a known immunosuppressive murine retroviral protein. P 15E 
has recently been reported by Thiel et ai.  (37) to have been well-conserved in 
viral phylogeny. Furthermore, Martin et al. (38) have reported that human DNA 
contains  sequences  that  hybridize  to  an  MuLV  reactive  fragment of cloned 
African  green  monkey DNA  and  Repaske  et  al.  (39)  recently reported  the 
isolation of 26  MuLV-related clones from a  human  DNA  library.  There has 
been a great deal of recent interest in oncogenes and their ability to neoplastically 
transform normal cells. We now propose the hypothesis that clinically relevant 
carcinogenesis might require the induction of additional gene products to those 
which  are  responsible  for  neoplastic  transformation  alone;  i.e.,  synthesis  of 
substances that subvert defensive processes of the host and allow the transformed 
cells to escape surveillance mechanisms. 
Summary 
Murine tumors contain low molecular weight factors that inhibit macrophage 
accumulation at inflammatory foci. Certain oncogenic murine leukemia viruses 
contain similar inhibitory activity and the active component of the retroviruses 
was shown to be the envelope protein P 15E. A number of murine malignant and 
nonmalignant cell lines, as well as primary tumors, have now been examined to 
determine whether production of retroviral P 15E or a  related protein is char- 
acteristic  of neoplastic  cells.  Tumor  lines  examined  included  the  Hep  129 
hepatocarcinoma, BP8 fibrosarcoma, RL1  lymphoma, and three variants of the 
B 16 melanoma. Tumor lines were virus negative by electron microscopy. Non- 
malignant cells examined included ST0,  3T3/BALB,  and 3T3/L1  fibroblasts 
and unstimulated, as well as mitogen-stimulated murine splenocytes. Cells were 
pulse-labeled with [35S]methionine, proteins immunoprecipitated with two mon- 
oclonal antibodies to P15E and analyzed by SDS-PAGE and gel fluorography. 
All tumor  lines synthesized a  ~  19,000-dalton  protein  that  co-migrated with 
retroviral P 15E on SDS-PAGE. None of the nonmalignant cells synthesized this 898  TUMOR  CELLS CONTAIN RETROVIRAL P15E-RELATED ANTIGEN 
protein. Two-dimensional gel electrophoresis of the proteins precipitated from 
two B16 melanoma lines by monocional anti-P15E showed them to be physico- 
chemically similar to P15E from Rauscher leukemia virus. A competition ELISA 
assay for P 15E was developed and confirmed the results obtained by metabolic 
labeling and demonstrated P15E-related antigens in the tumor cell lines and also 
in the ascites fluid of mice injected with Hep 129 cells.  More importantly, P15E 
antigens were expressed in both a spontaneous mammary adenocarcinoma and 
in a  primary methylcholanthrene-induced fibrosarcoma.  Nonmalignant tissues 
from  animals  bearing  these  tumors  contained  no  detectable  P15E  antigen. 
Extracts from the primary fibrosarcomas, when injected into the thighs of mice, 
inhibited the intraperitoneai accumulation of inflammatory macrophages. The 
inhibitory activity was specifically removed by absorption with monoclonai anti- 
body to P15E. 
These results suggest that synthesis of the immunosuppressive retroviral pro- 
tein  P15E,  or  a  very similar protein,  routinely occurs  during the  growth  of 
murine  neoplastic  cells.  This  P15E-related  protein  is  present  in  spontaneous 
murine primary tumors as  well as  in all  murine tumor cell  lines tested.  The 
expression of such proteins by transformed cells in vivo could confer a selective 
advantage for their sustained growth since they would be more likely to escape 
immune surveillance. 
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